MA49472A - Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole - Google Patents

Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole

Info

Publication number
MA49472A
MA49472A MA049472A MA49472A MA49472A MA 49472 A MA49472 A MA 49472A MA 049472 A MA049472 A MA 049472A MA 49472 A MA49472 A MA 49472A MA 49472 A MA49472 A MA 49472A
Authority
MA
Morocco
Prior art keywords
preparation process
intermediate preparation
derivative intermediate
methoxypyrrole derivative
methoxypyrrole
Prior art date
Application number
MA049472A
Other languages
English (en)
Other versions
MA49472B1 (fr
Inventor
Seung Chul Lee
Jeong-Taek Shin
Jeong Hyun Son
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MA49472A publication Critical patent/MA49472A/fr
Publication of MA49472B1 publication Critical patent/MA49472B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA49472A 2017-06-21 2018-06-21 Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole MA49472B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170078745A KR102233455B1 (ko) 2017-06-21 2017-06-21 4-메톡시피롤 유도체의 중간체 제조 방법
PCT/KR2018/006989 WO2018236153A1 (fr) 2017-06-21 2018-06-21 Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole

Publications (2)

Publication Number Publication Date
MA49472A true MA49472A (fr) 2020-04-29
MA49472B1 MA49472B1 (fr) 2022-01-31

Family

ID=64735783

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49472A MA49472B1 (fr) 2017-06-21 2018-06-21 Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole

Country Status (30)

Country Link
US (2) US11345660B2 (fr)
EP (1) EP3642181B1 (fr)
JP (1) JP6799178B2 (fr)
KR (1) KR102233455B1 (fr)
CN (1) CN110582482B (fr)
AU (1) AU2018288933B2 (fr)
BR (1) BR112019027323A2 (fr)
CA (1) CA3061713C (fr)
CL (1) CL2019003450A1 (fr)
CO (1) CO2019012689A2 (fr)
DO (1) DOP2019000291A (fr)
EC (1) ECSP19081847A (fr)
ES (1) ES2901701T3 (fr)
HR (1) HRP20211819T1 (fr)
HU (1) HUE057666T2 (fr)
JO (1) JOP20190265B1 (fr)
MA (1) MA49472B1 (fr)
MY (1) MY188800A (fr)
NZ (1) NZ758770A (fr)
PE (1) PE20210151A1 (fr)
PH (1) PH12019502865A1 (fr)
PL (1) PL3642181T3 (fr)
PT (1) PT3642181T (fr)
RS (1) RS62564B1 (fr)
RU (1) RU2737470C1 (fr)
SA (1) SA519410407B1 (fr)
SG (1) SG11201911164WA (fr)
SI (1) SI3642181T1 (fr)
TN (1) TN2019000301A1 (fr)
WO (1) WO2018236153A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
US10789690B2 (en) * 2018-03-07 2020-09-29 Adobe Inc. Masking non-public content
CN109867617A (zh) * 2019-04-03 2019-06-11 南京格亚医药科技有限公司 一种4-甲氧基吡咯中间体的制备方法
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
CN117326961B (zh) * 2023-09-27 2024-05-03 安徽峆一药业股份有限公司 一种非苏拉赞中间体的绿色合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
EP2336107B1 (fr) 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Inhibiteurs de pompe a protons
PL1919865T3 (pl) 2005-08-30 2011-09-30 Takeda Pharmaceuticals Co 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린
CN102088855A (zh) * 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
US8895558B2 (en) * 2008-10-02 2014-11-25 Green Cross Corporation Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2017164575A1 (fr) 2016-03-25 2017-09-28 Daewoong Pharmaceutical Co.,Ltd. Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) * 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Also Published As

Publication number Publication date
US11345660B2 (en) 2022-05-31
NZ758770A (en) 2022-01-28
KR102233455B1 (ko) 2021-03-29
CN110582482A (zh) 2019-12-17
JP2020519680A (ja) 2020-07-02
WO2018236153A1 (fr) 2018-12-27
PH12019502865A1 (en) 2020-12-07
EP3642181A4 (fr) 2020-12-09
JOP20190265A1 (ar) 2019-11-12
CA3061713C (fr) 2021-10-12
DOP2019000291A (es) 2019-12-15
SI3642181T1 (sl) 2022-04-29
CL2019003450A1 (es) 2020-03-27
RU2737470C1 (ru) 2020-11-30
SA519410407B1 (ar) 2022-06-14
US20200181080A1 (en) 2020-06-11
PT3642181T (pt) 2021-12-20
TN2019000301A1 (en) 2021-05-07
CO2019012689A2 (es) 2020-01-17
ECSP19081847A (es) 2019-11-30
AU2018288933A1 (en) 2019-11-21
KR20180138476A (ko) 2018-12-31
EP3642181B1 (fr) 2021-11-03
RS62564B1 (sr) 2021-12-31
AU2018288933B2 (en) 2020-12-10
EP3642181A1 (fr) 2020-04-29
SG11201911164WA (en) 2020-01-30
CA3061713A1 (fr) 2018-12-27
PL3642181T3 (pl) 2022-02-14
US20220259146A1 (en) 2022-08-18
JOP20190265B1 (ar) 2023-03-28
MY188800A (en) 2022-01-04
CN110582482B (zh) 2022-10-11
ES2901701T3 (es) 2022-03-23
BR112019027323A2 (pt) 2020-07-28
MA49472B1 (fr) 2022-01-31
PE20210151A1 (es) 2021-01-26
JP6799178B2 (ja) 2020-12-09
HRP20211819T1 (hr) 2022-03-04
HUE057666T2 (hu) 2022-06-28

Similar Documents

Publication Publication Date Title
MA49472A (fr) Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole
MA54253A (fr) Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines
MA52906A (fr) Procédé de préparation d'amg 416
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
MA50517A (fr) Procédé de préparation d'intermédiaire de dérivé de 4-méthoxypyrrole
MA48723A (fr) Procédé de production d'anticorps multispécifiques
MA48798A (fr) Procédé de production d'ozanimod
DK3635101T3 (da) Manipulerede ligasevarianter
MA52795A (fr) Dérivé de carbamoylpyridone polycyclique
MA52802A (fr) Dérivé de pyridone polycyclique
MA50796A (fr) Procédé de décomposition de phosphogypse
MA42423A (fr) Procédé de préparation d'un revêtement
IL260465B (en) A process for preparing an antibody-rifamycin conjugate
MA50169A (fr) Procédé de production d'un électrocatalyseur
IL267508B (en) A process for the preparation of 2-pyridylethyl carboxamide derivatives
MA54396A (fr) Procédé de préparation de n-phénylpyrazole-1-carboxamides
FR3038312B1 (fr) Procede de preparation de polyols
MA41790A (fr) Dérivé de morphinane
FR3048968B1 (fr) Procede de preparation d'alkylamines
MA42264A (fr) Procédé de préparation d'oltipraz
MA49555A (fr) Procédé amélioré de préparation d'imetelstat
DK3512518T3 (da) Buprenophinformuleringer med langvarig frigivelse
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
FR3049599B1 (fr) Procede de preparation de l'hexafluorobutadiene.
MA47014A (fr) Procédé de purification d'antibiotiques lipopeptidiques